Lower 6‐MMP/6‐TG Ratio May Be a Therapeutic Target in Pediatric Autoimmune Hepatitis

ABSTRACT Background: Azathioprine (AZA) is the mainstay of maintenance therapy in pediatric autoimmune hepatitis (AIH). The use of thiopurines metabolites to individualize therapy and avoid toxicity has not, however, been clearly defined. Methods: Retrospective analysis of children ⩽18 years diagnosed with AIH between January 2001 and 2016. Standard definitions were used for treatment response and disease flare. Thiopurine metabolite levels were correlated with the corresponding liver function test. Results: A total of 56 children (32 girls) were diagnosed with AIH at a median age of 11 years (interquartile range [IQR] 9). No difference in 6‐thioguanine‐nucleotide (6‐TG) levels (271[IQR 251] pmol/8 × 10 8 red blood cell vs 224 [IQR 147] pmol/8 × 10 8 red blood cell, P = 0.06) was observed in children in remission when compared with those who were not in remission. No correlation was observed between the 6‐TG and alanine aminotransferase levels (r = −0.179, P = 0.109) or between 6‐methyl‐mercaptopurine (6‐MMP) and alanine aminotransferase levels (r = 0.139, P = 0.213). The 6‐MMP/6‐TG ratio was significantly lower in patients who were in remission (2[7] vs 5 (10), P = 0.04). Using a quartile analysis, we found that having a ratio of <4 was significantly associated with being in remission with OR 2.50 (95% confidence interval 1.02–6.10), P = 0.047. Use of allopurinol with low‐dose AZA in 6 children with preferential 6‐MMP production brought about remission in 5/6 (83.3%). Conclusions: Thiopurine metabolite levels should be measured in patients with AIH who have experienced a loss of remission. A 6‐MMP/6‐TG ratio of <4 with the addition of allopurinol could be considered in these patients.